• Adjunct Assistant Professor, Family And Preventive Medicine
  • Assistant Professor, Population Health Sciences

Research Statement

I am trained in the design and analysis of clinical trials and observational studies. 

My students and I develop methods that increase a study’s efficiency and effectiveness.  Our current emphasis is in developing covariate-adjusted randomization and sample-size adaptive monitoring methods.  

These methods reduce on average the noise in estimating an effect, improve the ability to study key subgroups, and allow for following studies until drawing clinically meaningful conclusions regarding the strength of the true effect.

Research Keywords

  • Causal Inference
  • Adaptive Monitoring Schemes
  • Covariate-Adjusted Randomization
  • Statistical Consulting


  • Chipman J., Greevy RA., Mayberry L., Blume JD., Adaptively Monitoring Clinical Trials with Second-Generation p-values. Brigham Young University, Provo, UT. , , 2018.
  • Chipman J., Mayberry L., Greevy RA. Techniques for Matched Randomization in Sequential Enrollment Trials. Dana-Farber Cancer Institute, Boston, MA. , , 2017.
  • Chipman J., Beck C., Greevy RA., Good Practices and Implementation Methods for Optimally Stratified Randomization. Midwest Biopharmaceutical Statistics Workshop, Muncie, IN. , , 2016.
  • Chipman J, GreevyJr RA, Mayberry L, Blume JD. Adaptive Monitoring of Clinical Trials Using the Second Generation p-value. Society of Clinical Trials Annual Meeting, Portland, OR. , , 2018.
  • Chipman J., Mayberry L., Greevy RA. Techniques for Matched Randomization in Sequential Enrollment Trials. Joint Statistical Meetings, Baltimore, MD. , , 2017.
  • Chipman J, Braun D. Simpson’s Paradox in the IDI. Eastern North American Region International Biometric Society, Miami, FL. , , 2015.
  • Chipman J., Greevy RA., Mayberry L., Blume JD., Adaptive Monitoring of Clinical Trials Using the Second Generation p-value. American Statistical Association – Biopharmaceutical Section, Washington, DC. Poster, Presented, 2018.
  • Chipman J., Mayberry L, Greevy RA, Practical Recommendations for Matched Sequential Randomization. Clinical and Translational Science, Washington, DC. Poster, Presented, 2016.
  • Chipman J., Braun D., Simpson's Paradox in the Integrated Discrimination Improvement. Joint Statistical Meetings, Seattle, WA. Poster, Presented, 2015.


  • English, Fluent.
  • Portuguese, Fluent.


  • Chipman J (date unknown). Restricted Randomization: Pros and Cautions. (pp. 51-60). CRC Press. Accepted, .
  • Pencina MJ, Chipman J, Steyerberg EW, Braun D, Fine JP, D'Agostino RB Sr (date unknown). Authors' response to comments. Vol. 36, 4511-4513. Accepted, .
  • Chipman J, Braun D (date unknown). Simpson's paradox in the integrated discrimination improvement. Vol. 36, 4468-4481. Accepted, .
  • Min JY, Hackstadt AJ, Griffin MR, Greevy RA Jr, Chipman J, Grijalva CG, Hung AM, Roumie CL (date unknown). Evaluation of weight change and hypoglycaemia as mediators in the association between insulin use and death. Vol. 21, 2626-2634. Accepted, .
  • Swami U, Isaacsson Velho P, Nussenzveig R, Chipman J, Sacristan Santos V, Erickson S, Dharmaraj D, Alva AS, Vaishampayan UN, Esther J, Hahn AW, Maughan BL, Antonarakis ES, Agarwal N (date unknown). Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. Vol. 78, 652-656. Accepted, .
  • Coletta AM, Playdon MC, Baron KG, Wei M, Kelley K, Vaklavas C, Beck A, Buys SS, Chipman J, Ulrich CM, Walker D, White S, Oza S, Zingg RW, Hansen PA (date unknown). The association between time-of-day of habitual exercise training and changes in relevant cancer health outcomes among cancer survivors. Vol. 16, e0258135. Accepted, .
  • Roumie CL, Chipman J, Min JY, Hackstadt AJ, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Griffin MR (date unknown). Association of Treatment With Metformin vs Sulfonylurea With Major Adverse Cardiovascular Events Among Patients With Diabetes and Reduced Kidney Function. 1-11. Accepted, .
  • Chang P, Szymanski KM, Dunn RL, Chipman JJ, Litwin MS, Nguyen PL, Sweeney CJ, Cook R, Wagner AA, DeWolf WC, Bubley GJ, Funches R, Aronovitz JA, Wei JT, Sanda MG (date unknown). Expanded prostate cancer index composite for clinical practice: development and validation of a practical health related quality of life instrument for use in the routine clinical care of patients with prostate cancer. Vol. 186, 865-72. Accepted, .
  • Berger VW, Bour LJ, Carter K, Chipman JJ, Everett CC, Heussen N, Hewitt C, Hilgers RD, Luo YA, Renteria J, Ryeznik Y, Sverdlov O, Uschner D, Randomization Innovative Design Scientific Working Group. (date unknown). A roadmap to using randomization in clinical trials. Vol. 21, 168. Accepted, .
  • Casper AC, Parsons MW, Chipman J, Burt LM Jr, Suneja G, Maurer KA, Gaffney DK (date unknown). Risk of secondary malignancies in ovarian cancer survivors: 52,680 patients analyzed with over 40 years of follow-up. Vol. 162, 454-460. Accepted, .
  • Sanda MG, Feng Z, Howard DH, Tomlins SA, Sokoll LJ, Chan DW, Regan MM, Groskopf J, Chipman J, Patil DH, Salami SS, Scherr DS, Kagan J, Srivastava S, Thompson IM Jr, Siddiqui J, Fan J, Joon AY, Bantis LE, Rubin MA, Chinnayian AM, Wei JT, and the EDRN-PCA3 Study Group., Bidair M, Kibel A, Lin DW, Lotan Y, Partin A, Taneja S (date unknown). Association Between Combined TMPRSS2:ERG and PCA3 RNA Urinary Testing and Detection of Aggressive Prostate Cancer. Vol. 3, 1085-1093. Accepted, .
  • Mazzola E, Chipman J, Cheng SC, Parmigiani G (date unknown). Recent BRCAPRO upgrades significantly improve calibration. Vol. 23, 1689-95. Accepted, .
  • Presley CA, Chipman J, Min JY, Grijalva CG, Greevy RA, Griffin MR, Roumie CL (date unknown). Evaluation of Frailty as an Unmeasured Confounder in Observational Studies of Antidiabetic Medications. Vol. 74, 1282-1288. Accepted, .
  • Chu PY, Hackstadt AJ, Chipman J, Griffin MR, Hung AM, Greevy RA Jr, Grijalva CG, Elasy T, Roumie CL (date unknown). Hospitalization for Lactic Acidosis Among Patients With Reduced Kidney Function Treated With Metformin or Sulfonylureas. Vol. 43, 1462-1470. Accepted, .
  • Kishi T, Chipman J, Evereklian M, Nghiem K, Stetler-Stevenson M, Rick ME, Centola M, Miller FW, Rider LG (date unknown). Endothelial Activation Markers as Disease Activity and Damage Measures in Juvenile Dermatomyositis. Vol. 47, 1011-1018. Accepted, .
  • Chipman J, Drohan B, Blackford A, Parmigiani G, Hughes K, Bosinoff P (date unknown). Providing access to risk prediction tools via the HL7 XML-formatted risk web service. Vol. 140, 187-93. Accepted, .
  • Biswas S, Atienza P, Chipman J, Hughes K, Barrera AM, Amos CI, Arun B, Parmigiani G (date unknown). Simplifying clinical use of the genetic risk prediction model BRCAPRO. Vol. 139, 571-9. Accepted, .
  • Min JY, Presley CA, Wharton J, Griffin MR, Greevy RA Jr, Hung AM, Chipman J, Grijalva CG, Hackstadt AJ, Roumie CL (date unknown). Accuracy of a composite event definition for hypoglycemia. Vol. 28, 625-631. Accepted, .
  • Min JY, Griffin MR, Chipman J, Hackstadt AJ, Greevy RA, Grijalva CG, Hung AM, Roumie CL (date unknown). Recent metformin adherence and the risk of hypoglycaemia in the year following intensification with a sulfonylurea. Vol. 36, 482-490. Accepted, .
  • Mihalcik S, Chipman J, Sanda M, Kaplan I, Crociani C, Chang P, PROST-QA Consortium (date unknown). Predicting erectile function following radiation therapy for prostate cancer at the point of care. Vol. 195, e150. Accepted, .
  • Hoppe BS, Michalski JM, Mendenhall NP, Morris CG, Henderson RH, Nichols RC, Mendenhall WM, Williams CR, Regan MM, Chipman JJ, Crociani CM, Sandler HM, Sanda MG, Hamstra DA (date unknown). Comparative effectiveness study of patient-reported outcomes after proton therapy or intensity-modulated radiotherapy for prostate cancer. Vol. 120, 1076-82. Accepted, .
  • Presley CA, Min JY, Chipman J, Greevy RA, Grijalva CG, Griffin MR, Roumie CL (date unknown). Validation of an algorithm to identify heart failure hospitalisations in patients with diabetes within the veterans health administration. Vol. 8, e020455. Accepted, .
  • Chipman JJ, Sanda MG, Dunn RL, Wei JT, Litwin MS, Crociani CM, Regan MM, Chang P (date unknown). Measuring and predicting prostate cancer related quality of life changes using EPIC for clinical practice. Vol. 191, 638-45. Accepted, .
  • Kazer MW, Bailey DE Jr, Chipman J, Psutka SP, Hardy J, Hembroff L, Regan M, Dunn RL, Crociani C, Sanda MG (date unknown). Uncertainty and perception of danger among patients undergoing treatment for prostate cancer. Vol. 111, E84-91. Accepted, .
  • Vicier C, Werner L, Chipman J, Harshman LC, Patil DH, Fichorova RN, Rider JR, Sanda MG, Mucci LA, Sweeney CJ (date unknown). Elevated Serum Cytokines and Trichomonas vaginalis Serology at Diagnosis Are Not Associated With Higher Gleason Grade or Lethal Prostate Cancer. Vol. 17, 32-37. Accepted, .
  • Sirohi D, Chipman J, Barry M, Albertson D, Mahlow J, Liu T, Raps E, Haaland B, Sayegh N, Li H, Rathi N, Sharma P, Agarwal N, Knudsen B (date unknown). Histologic Growth Patterns in Clear Cell Renal Cell Carcinoma Stratify Patients into Survival Risk Groups. Accepted, .
  • Kerrigan K, Jo Y, Chipman J, Haaland B, Puri S, Akerley W, Patel S (date unknown). A Real-World Analysis of the Use of Systemic Therapy in Malignant Pleural Mesothelioma and the Differential Impacts on Overall Survival by Practice Pattern. Vol. 3, 100280. Accepted, .
  • Mihalcik SA, Chipman JJ, Sanda MG, Regan MM, Kaplan ID, Wagner AA, Crociani CM, Chang P, PROST-QA Consortium. (date unknown). Predicting erectile function following external beam radiation therapy or brachytherapy for prostate cancer using EPIC-CP. Vol. 8, 445-451. Accepted, .
  • Biswas S, Atienza P, Chipman J, Blackford AL, Arun B, Hughes K, Parmigiani G (date unknown). A two-stage approach to genetic risk assessment in primary care. Vol. 155, 375-83. Accepted, .
  • Bigler ED, Abildskov TJ, Petrie JA, Johnson M, Lange N, Chipman J, Lu J, McMahon W, Lainhart JE (date unknown). Volumetric and voxel-based morphometry findings in autism subjects with and without macrocephaly. Vol. 35, 278-95. Accepted, .